Biologic therapies for inflammatory eye disease
L Lim, EB Suhler, JR Smith - Clinical & experimental …, 2006 - Wiley Online Library
The era of biologic medical therapies provides new options for patients with treatment‐
resistant inflammatory eye disease. In this review, the authors summarize current published …
resistant inflammatory eye disease. In this review, the authors summarize current published …
The future of uveitis treatment
P Lin, EB Suhler, JT Rosenbaum - Ophthalmology, 2014 - Elsevier
Uveitis is a heterogeneous collection of diseases with polygenic and environmental
influences. This heterogeneity presents challenges in trial design and selection of end …
influences. This heterogeneity presents challenges in trial design and selection of end …
[HTML][HTML] Adalimumab in patients with active noninfectious uveitis
GJ Jaffe, AD Dick, AP Brézin, QD Nguyen… - … England Journal of …, 2016 - Mass Medical Soc
Background Patients with noninfectious uveitis are at risk for long-term complications of
uncontrolled inflammation, as well as for the adverse effects of long-term glucocorticoid …
uncontrolled inflammation, as well as for the adverse effects of long-term glucocorticoid …
Methotrexate for ocular inflammatory diseases
S Gangaputra, CW Newcomb, TL Liesegang… - Ophthalmology, 2009 - Elsevier
PURPOSE: To evaluate the outcome of treatment with methotrexate for noninfectious ocular
inflammation. DESIGN: Retrospective cohort study. PARTICIPANTS: Patients with …
inflammation. DESIGN: Retrospective cohort study. PARTICIPANTS: Patients with …
A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes
EB Suhler, JR Smith, MS Wertheim… - Archives of …, 2005 - jamanetwork.com
Objective Infliximab, a monoclonal antibody against tumor necrosis factor α, is approved by
the US Food and Drug Administration for treatment of numerous autoimmune disorders. We …
the US Food and Drug Administration for treatment of numerous autoimmune disorders. We …
Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports
FW Fraunfelder, EB Suhler… - Cutaneous and ocular …, 2010 - Taylor & Francis
Objective: To report a possible association between hepatitis B vaccine and uveitis.
Methods: Spontaneous reports from the National Registry of Drug-Induced Ocular Side …
Methods: Spontaneous reports from the National Registry of Drug-Induced Ocular Side …
Azathioprine for ocular inflammatory diseases
S Pasadhika, JH Kempen, CW Newcomb… - American journal of …, 2009 - Elsevier
PURPOSE: To evaluate treatment outcomes of azathioprine for noninfectious ocular
inflammatory diseases. DESIGN: Retrospective cohort study. METHODS: Medical records of …
inflammatory diseases. DESIGN: Retrospective cohort study. METHODS: Medical records of …
Mycophenolate mofetil for ocular inflammation
E Daniel, JE Thorne, CW Newcomb, SS Pujari… - American journal of …, 2010 - Elsevier
PURPOSE: To evaluate mycophenolate mofetil as a single noncorticosteroid
immunosuppressive treatment for noninfectious ocular inflammatory diseases. DESIGN …
immunosuppressive treatment for noninfectious ocular inflammatory diseases. DESIGN …
Cyclosporine for ocular inflammatory diseases
RO Kaçmaz, JH Kempen, C Newcomb, E Daniel… - Ophthalmology, 2010 - Elsevier
PURPOSE: To evaluate the clinical outcomes of cyclosporine treatment for noninfectious
ocular inflammation. DESIGN: Retrospective cohort study. PARTICIPANTS: A total of 373 …
ocular inflammation. DESIGN: Retrospective cohort study. PARTICIPANTS: A total of 373 …
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study
JH Kempen, E Daniel, JP Dunn, CS Foster… - Bmj, 2009 - bmj.com
Context Whether immunosuppressive treatment adversely affects survival is unclear.
Objective To assess whether immunosuppressive drugs increase mortality. Design …
Objective To assess whether immunosuppressive drugs increase mortality. Design …